A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
This is a randomized, double-blind, placebo-controlled phase III study to evaluate GLS-010 plus platinum-containing chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer.
Epistemonikos ID: 0521107b1f7b10bdedcd8347407c891b3dd28417
First added on: Feb 19, 2024